Outcomes of Patients with Chronic Heart Failure and Iron Deficiency Treated with Intravenous Iron: A Meta-analysis

ISSN: 2212-4063 (Online)
ISSN: 1871-529X (Print)

Volume 16, 3 Issues, 2016

Download PDF Flyer

Cardiovascular & Hematological Disorders-Drug Targets

Formerly: Current Drug Targets - Cardiovascular & Hematological Disorders

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Garry X. Shen
University of Manitoba
Winnipeg, MB

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Outcomes of Patients with Chronic Heart Failure and Iron Deficiency Treated with Intravenous Iron: A Meta-analysis

Cardiovascular & Hematological Disorders-Drug Targets, Volume 12 (E-pub ahead of print)

Author(s): Mahim Kapoora, Mark D. Schleinitz, Anthony Gemignani and Wen-Chih Wu.

Affiliation: Department of Medicine, Alpert Medical School of Brown University, Rhode Island Hospital, 593 Eddy Street, Providence, Rhode Island 02904, USA


Background: Trials studying iron repletion in patients with chronic heart failure (CHF) and iron deficiency are underpowered to find consistent hard endpoint (mortality and hospitalization) reductions. We conducted a meta-analysis of controlled trials to examine the effects of iron repletion on these parameters.

Methods and Results: Pubmed, CENTRAL, EMBASE and NIH Clinical Trials databases were searched for controlled trials utilizing intravenous iron, with or without erythropoietin, in patients with CHF with NYHA class ≥ II, iron deficiency, and left ventricular dysfunction. Data regarding hospitalizations, mortality, adverse events, NYHA class, and ejection fraction were extracted, analyzed for heterogeneity, and pooled using the DerSimonian and Laird random effects model. We identified 5 controlled trials (n = 631 patients). Patients treated with intravenous iron had significant reductions in hospitalizations (OR 0.26, 95% CI 0.08-0.80), adverse events (OR 0.35, 95% CI 0.21-0.60), NYHA class (mean improvement 1.2 classes, 95% CI 0.69-1.78, and LVEF (mean improvement 5.0%, 95% CI 0.13-9.80) but no relationship was found on mortality (OR 0.66, 95% CI 0.30-1.44).

Conclusion: Treatment of iron deficiency in patients with CHF reduces the risk of hospitalizations without increased adverse events, suggesting its role as a potential therapeutic target in this group of patients.


Anemia, chronic heart failure, EPO, erythropoietin, heart failure, intravenous iron, iron deficiency.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 12
First Page: 1
Last Page: 10
Page Count: 10
Global Biotechnology Congress 2016Drug Discovery and Therapy World Congress 2016

Related Journals

Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science